Kings Research™ presents this information in its report titled, “Antibody Discovery Market Size, Share & Industry Analysis, By Technique (Phage, Display Technology, Single B Cell Immunization, Hybridoma Technology & Others), By Antibody Type (Humanized Antibody, Human Antibody, Chimeric Antibody, Murine Antibody), By End-User, and Regional Analysis, 2024-2031"

The global Antibody Discovery Market size was valued at USD 6.36 billion in 2023 and is projected to grow from USD 6.96 billion in 2024 to USD 13.20 billion by 2031, exhibiting a CAGR of 9.56% during the forecast period. The market is rapidly expanding due to increased demand for innovative immunotherapies and the development of new antibody-based treatments.

The antibody discovery market is also witnessing a shift toward the development of antibody-drug conjugates (ADCs), which combine the specificity of antibodies with the cytotoxic potency of small-molecule drugs. ADCs have emerged as a powerful therapeutic modality, particularly in oncology, where they can deliver targeted payloads to cancer cells while sparing healthy tissues. Several ADCs have been approved for the treatment of various cancers, and their success has spurred further research and development in this area.

Pharmaceutical and biotechnology companies are investing heavily in antibody discovery platforms to stay competitive in the rapidly evolving healthcare landscape. The growing emphasis on personalized medicine, where treatments are tailored to individual patients based on their genetic and molecular profiles, has increased the demand for antibody-based therapies. Companies are leveraging advanced technologies such as artificial intelligence (AI) and machine learning (ML) to accelerate the discovery process, predict antibody-antigen interactions, and optimize therapeutic candidates. These technologies are helping to streamline the antibody discovery process, reduce costs, and improve the success rate of therapeutic development.

Browse Full Report Details @ https://www.kingsresearch.com/antibody-discovery-market-983

List of Key Companies in Antibody Discovery Market

• Eurofins Discovery
• Evotec
• Twist Bioscience
• Genscript
• Biocytogen
• Sartorius AG
• Danaher Corporation
• Fairjourney Biologics S.A
• Creative Biolabs

Antibodies are proteins produced by the immune system in response to the presence of foreign substances, such as bacteria, viruses, or toxins. These proteins are highly specific and have a remarkable ability to bind to antigens, neutralizing them or marking them for destruction by other immune cells. The discovery of antibodies, particularly monoclonal antibodies, has revolutionized the field of therapeutics. Monoclonal antibodies are engineered in laboratories to recognize and bind to a single specific target, offering precise treatment for a variety of conditions, including cancers, infectious diseases, and inflammatory disorders.

The increasing prevalence of chronic diseases, especially cancer, and autoimmune disorders has propelled the demand for antibody-based therapies. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, and its incidence continues to rise. This has fueled the development of new and innovative antibody therapeutics that target cancer cells with greater precision, minimizing damage to healthy tissues. The antibody discovery process, which includes antigen identification, hybridoma technology, phage display, and next-generation sequencing, has enabled researchers to discover novel antibodies with enhanced efficacy and safety profiles.

Antibody Discovery Market was valued at USD 6.36 billion in 2023 and is projected to grow from USD 6.96 billion in 2024 to USD 13.20 billion by 2031, exhibiting a CAGR of 9.56% during the forecast period. The market is rapidly expanding due to increased demand for innovative immunotherapies and the development of new antibody-based treatments.

Antibody Discovery Market Segments:

By Techniques

• Phage Display Technology
• Single B Cell Immunization
• Hybridoma Technology
• Next-generation Sequencing (NGS)
• RT-PCR
• Flow Cytometry
• Fluorescence-activated Cell Sorting (FACS)

By Antibody Types

• Humanized Antibody
• Human Antibody
• Chimeric Antibody
• Murine Antibody

Europe is another significant market for antibody discovery, with countries such as Germany, the United Kingdom, and France leading the region's growth. The European Medicines Agency (EMA) has approved several monoclonal antibodies for therapeutic use, and the region's strong focus on R&D, coupled with favorable regulatory frameworks, is driving the adoption of antibody-based therapies. The growing trend toward precision medicine and the increasing number of clinical trials for antibody therapeutics are further contributing to market expansion in Europe.

Several key players are dominating the global antibody discovery market, including companies such as Genmab, AbCellera, Adimab, and Aldevron. These companies are at the forefront of innovation, leveraging cutting-edge technologies and platforms to accelerate the discovery and development of novel antibody therapeutics. They are also investing in strategic collaborations and partnerships to expand their product pipelines and enhance their competitive edge. Additionally, the rise of contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) is providing pharmaceutical companies with the necessary expertise and infrastructure to streamline antibody discovery and development.

In recent years, there has been a growing focus on bispecific antibodies, which are designed to bind to two different antigens simultaneously. This novel class of antibodies has shown great promise in treating complex diseases, such as cancer and autoimmune disorders, by targeting multiple disease pathways. Several bispecific antibodies are currently in clinical development, and their potential to offer enhanced therapeutic efficacy is generating significant interest in the market.

Contact Us:

Kings Research

Website: https://www.kingsresearch.com

E-mail: business@kingsresearch.com

Phone: (+1) 888 328 2189